Brigatinib is a tyrosine kinase inhibitor designed to inhibitabroad range of ALK kinase domain mutations, such as the F1174C/V,I1171N, and G120R mutations reported to occur as treatment resistanceresponse to crizotinib or second-generation inhibitors like ceritiniband alectinib.14,15 However, brigatinib is also indicatedfor primary EML4–ALK mutation-positive NSCLC.16 Recently, brigatinib was proposed as a dual TKI as it alsoinhibited mutated EGFR in vitro. This evidence concerns the gene ALK and non-small cell lung carcinoma.